Therapeutic vaccine for chronic diseases after the COVID-19 Era.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Hironori NakagamiRyuichi Morishita

Abstract

There is currently a respiratory disease outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After rapid development, RNA vaccines and adenoviral vector vaccines were approved within a year, which has demonstrated the strong impact of preventing infectious diseases using gene therapy technology. Furthermore, intensive immunological analysis has been performed to evaluate the efficiency and safety of these vaccines, potentially allowing for rapid progress in vaccine technology. After the coronavirus disease 2019 (COVID-19) era, the novel vaccine technology developed will expand to other vaccines. We have been developing vaccines for chronic diseases, such as hypertension, for >10 years. Regarding the development of vaccines against self-antigens (i.e., angiotensin II), the vaccine should efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. Therefore, the epitope vaccine approach has been proposed to induce antibody production in response to a combination of a B cell epitope and exogenous T cell epitopes through major histocompatibility complex molecules. When these vaccines are established as therapeutic options for hypertension, their adminis...Continue Reading

References

Jun 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J B MichelJ Ménard
Jul 8, 1999·European Journal of Pharmacology·F L FierensG Vauquelin
Nov 2, 1999·Micron : the International Research and Review Journal for Microscopy·J R Harris, J Markl
Feb 15, 2001·Circulation·M Burnier
Aug 16, 2003·Science·Hedda WardemannMichel C Nussenzweig
Mar 1, 1964·The Journal of Experimental Medicine·S D DEODHARH GOLDBLATT
Sep 20, 2005·Nature Biotechnology·Shang-Zhong XuDavid J Beech
Jan 13, 2006·Journal of Molecular Modeling·Camelia Baleanu-Gogonea, Sadashiva Karnik
Feb 15, 2011·Annual Review of Immunology·Shane Crotty
Dec 14, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tatsuhiko AzegamiHiroshi Itoh
Apr 2, 2017·Stroke; a Journal of Cerebral Circulation·Kouji WakayamaRyuichi Morishita
Dec 15, 2019·Geriatrics & Gerontology International·Hironori Nakagami
May 21, 2020·Nature Communications·Trevor R F SmithKate E Broderick
Jul 15, 2020·The New England Journal of Medicine·Lisa A JacksonUNKNOWN mRNA-1273 Study Group
Jul 16, 2020·Journal of Hypertension·Ryo NakamaruHiromi Rakugi
Aug 7, 2020·Nature·Kizzmekia S CorbettBarney S Graham
Aug 14, 2020·Nature·Mark J MulliganKathrin U Jansen
Sep 24, 2020·Nature·Florian Krammer
Sep 30, 2020·The New England Journal of Medicine·Evan J AndersonUNKNOWN mRNA-1273 Study Group
Oct 15, 2020·The New England Journal of Medicine·Edward E WalshWilliam C Gruber
Dec 11, 2020·The New England Journal of Medicine·Fernando P PolackUNKNOWN C4591001 Clinical Trial Group
Mar 28, 2021·International Immunology·Hironori Nakagami

❮ Previous
Next ❯

Software Mentioned

Moderna

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Circulation Journal : Official Journal of the Japanese Circulation Society
Ryo NakamaruRyuichi Morishita
© 2021 Meta ULC. All rights reserved